A detailed history of Quent Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Quent Capital, LLC holds 24 shares of APLS stock, worth $869. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24
Previous 24 -0.0%
Holding current value
$869
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$55.39 - $72.47 $941 - $1,231
17 Added 242.86%
24 $1,000
Q4 2023

Jun 14, 2024

BUY
$37.14 - $64.82 $74 - $129
2 Added 40.0%
7 $0
Q4 2023

Jan 19, 2024

BUY
$37.14 - $64.82 $74 - $129
2 Added 40.0%
7 $0
Q3 2023

Jun 14, 2024

SELL
$23.65 - $89.22 $449 - $1,695
-19 Reduced 79.17%
5 $0
Q3 2023

Oct 10, 2023

BUY
$23.65 - $89.22 $118 - $446
5 New
5 $0

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.98B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.